NCT06316973

A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CS-1103 Following Single, Ascending Intravenous Dose Administration in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Clear Scientific, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.

Conditions

• Substance Use Disorders
• Methamphetamine Abuse
• Methamphetamine Intoxication

Interventions

Type	Name	Description
DRUG	CS-1103	CS-1103 for infusion
DRUG	Sterile Saline	Sterile Saline for Injection

Timeline

• Start date: 2024-02-07
• Primary completion: 2024-05-30
• Completion: 2024-06-06
• First posted: 2024-03-19
• Last updated: 2025-11-10
• Results posted: 2025-11-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study